Background--Recent randomized controlled clinical trials have provided solid evidence that mechanical thrombectomy (MT) coupled with best medical therapy (BMT) improve functional outcomes of acute ischemic stroke patients with large vessel occlusion compared with BMT alone. However, they provided inconclusive evidence on the benefit of MT on mortality.
D espite the significant decrease of stroke mortality risk during the past decade, stroke still remains the second global cause of mortality. 1 Recent randomized controlled clinical trials (RCTs) have provided solid evidence that mechanical thrombectomy (MT) coupled with best medical therapy (BMT) improve functional outcomes of acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) compared with BMT alone. However, except for one, they were inconclusive on the benefit of MT +BMT on mortality. 2 In the present systematic review and meta-analysis, we evaluated the association of MT+BMT compared with BMT alone with the risk of 3-month mortality in AIS patients with LVO using data from eligible RCTs.
Methods
The present systematic review and meta-analysis adheres to the Journal of the American Heart Association's ( JAHA) implementation of the Transparency and Openness Promotion guidelines, and is presented according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses statement.
We searched for RCTs providing 3-month mortality rates in LVO patients randomized to MT+BMT or BMT alone. Literature search in MEDLINE, SCOPUS and CENTRAL (the Cochrane Central Register of Controlled Trials) was performed using the following terms in combination: "endovascular therapy," "endovascular treatment," "endovascular reperfusion therapy," "mechanical thrombectomy," "thrombectomy," "acute ischemic stroke," "cerebrovascular ischemia" and "stent retriever," "thromboaspiration," "stroke," and "large vessel occlusion." The complete algorithm used in MEDLINE database search is available in Data S1. Eligible studies were also sourced from the hand-searching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses. No language or other search restriction was applied. Last literature search was performed on June 11, 2019. No time or protocol restrictions were implemented, and thus we included all RCTs providing mortality rates on the 3-month follow-up. Per study protocol we excluded from further evaluation all observational studies, case reports, case series, and studies not providing 3-month mortality rates. We also excluded studies using first generation thrombectomy devices and studies with possibility of enrolling patients without LVO. Reference lists of all articles that met the inclusion criteria and of relevant review articles were examined to identify studies that may have been missed by the initial database search.
We performed quality control for each eligible study with the Cochrane risk of bias assessment tool. Literature search, data abstraction, and bias identification were independently performed by 2 authors (AHK, KM) and all emerging conflicts were resolved after consultation of the senior author (GT).
Using aggregate data from available RCTs we performed random-effects meta-analyses on the risk of 3-month mortality and the probability of functional improvement at 3 months in the ordinal scale between patients randomized to MT+BMT or BMT alone. Mortality rates in each group were calculated after implementing the variance-stabilizing double arcsine Freeman-Tukey transformation. Heterogeneity was assessed with the I 2 and Cochran Q statistics. Number needed to treat was calculated using the formula number needed to treat=1/[(1-Risk Ratio) x mortality rate in BMT alone group]. 3 To identify potential predictors of mortality risk we performed univariable meta-regression analyses for all baseline characteristics reported as percentages or mean values (for continuous variables) and being provided in ≥10 publications. Publication bias across individual studies was graphically evaluated by funnel plot inspection and with the Egger statistical test.
All statistical analyses were conducted using the Cochrane Collaboration 
Data Availability Statement
All data used for analyses are available within the main manuscript and its associated supplemental file.
Results
Our literature search identified 11 eligible RCTs, including a total of 2460 patients ( Figure S1 ). 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Excluded studies with reasons for exclusion are outlined in Table S1 . Patient characteristics receiving MT+BMT or BMT alone are summarized in Table. Risk of bias was considered low in most domains, except for the risk of performance bias because of the open blinded design ( Figures S2 and S3 ), while marked as unclear in the corresponding domains of one RCT that could
Clinical Perspective
What Is New?
• Recent randomized controlled clinical trials have provided inconclusive evidence on the benefit of mechanical thrombectomy (MT) on mortality of patients with acute ischemic stroke attributable to large vessel occlusion. • Our meta-analysis provides evidence that MT reduces by 17% the risk of 3-month mortality of acute ischemic stroke patients with large vessel occlusion. • The reduction of mortality risk with MT appears not to be moderated by individual patient or procedural characteristics.
What Are the Clinical Implications?
• MT should be performed in 31 acute ischemic stroke patients with large vessel occlusion to save the life of 1 more patient. • MT is also associated with improved functional outcomes, and therefore the reduction in mortality by MT does not seem to be associated with increased likelihood for functional disability.
Table.
Characteristics of patients randomized to receive mechanical thrombectomy within included studies.
Study Name
Publishing, y not be sufficiently assessed because of the lack of full-text publications at the time of our literature search. 9 In the overall analysis, MT+BMT was associated with a significantly lower risk of all-cause mortality at 3 months compared with BMT alone (risk ratio=0.83, 95% CI: 0.69-0.99; P=0.04; Figure 1 ), without heterogeneity across the included studies (I 2 =3%, P for Cochran Q=0.41). No evidence of publication bias was present in both funnel plot inspection ( Figure S4 ) and Egger statistical test (P=0.762). The pooled rates of 3-month mortality were 15% (95% CI: 12%-19%; Figure S5 ) and 19% (95% CI: 16%-23%; Figure S6 ), respectively, in the MT+BMT and BMT alone groups. MT+BMT was also associated with a higher probability of functional improvement in the whole distribution of the modified Rankin Scale scores at 3 months (common odds ratio=2.13, 95% CI: 1.77-2.57), with no significant heterogeneity within studies (I 2 =38%, P for Cochran Q=0.10; Figure 2 ).
In meta-regression analyses (Table S2) 
Discussion
Our meta-analysis provides evidence that MT coupled with BMT reduce the risk of 3-month mortality. This association appears not to be moderated by individual patient or procedural characteristics. Based on the risk reduction and pooled 3-month mortality rates of BMT (19%) in the 11 RCTs, it appears that MT should be performed in 31 AIS patients with LVO in addition to BMT to save the life of 1 additional patient. MT was also associated with improved functional outcomes across all ranks of modified Rankin Scale (ordinal shift analysis), and therefore the reduction in mortality by MT does not seem to be associated with increased likelihood for functional disability.
Our results are in accordance with a previous nationwide US study suggesting a steady decrease in the mortality risk of AIS patients after the introduction of MT. 14 Although numerous clinical and procedural parameters have been reported as potential predictors of all-cause mortality risk following MT, we uncovered no moderating effect in our meta-regression analyses. Despite the fact that futile recanalization was associated with increased mortality risk in a North-American stroke registry, proximal vessel occlusion, high National Institutes of Health Stroke Scale scores, and the need for rescue therapy emerged as the only independent predictors of mortality, posing an increased risk independent of successful reperfusion. 15 The present meta-analysis is the first to date to have the adequate statistical power to answer the question on the impact of MT on 3-month mortality (Table S3 ). Despite the strengths of the present report several limitations also need to be acknowledged. First, it should be highlighted that we combined studies with heterogeneous clinical and neuroimaging inclusion criteria to provide an estimate of the cumulative impact of MT on all-cause mortality in different settings. Despite the disparities between study protocols of included studies, no evidence of heterogeneity was detected between study estimates. Second, it should be acknowledged that we were unable to assess the causes of mortality in included RCTs that further limited conducting subgroup analyses according to the corresponding cause (ie, cardiovascular mortality versus mortality associated with neurological deterioration). Finally, the lack of significant associations in meta-regression analyses could also be attributed to the potential presence of aggregation bias (ecological fallacy).
Conclusions
MT combined with BMT provide survival benefits in addition to functional independence in AIS patients with LVO. The relative risk reduction in 3-month mortality corresponds to 17% with a number needed to treat of 31.
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